Get started
Royal Unibrew The stock is in a declining trend channel. It appears scroll. of the long moving averages and charts. Looking back, there will be a support around 480 (5 year chart). RSI 21 and OBV have gone up and then flattened out somewhat when you look at the last 40 days. The last week some hammer candlestick pointing down. MA and oscillators stand one month on neutral. The price has been in a flat development for a little month and a clear movement up or down from here will give direction at least in the short term. Consider the stock technically weak negative in the medium term. This is a technical analysis, but fundamental analysts are preferably positive about the stock. Remember you need do your own research and assessment before buying and selling. Disclaimer: I hold a position in the stock. Sources: Trading View
OMXCOP:RBREW
by scorpiris
A defensive stock in a rising trend Measured by value, Novo Nordisk is Northern Europe's largest business and headquartered in Bagsværd, Denmark. It's a defensive stock that's done well. It is considered a bit of a weakness that they have the majority of their income on few products, but on the other hand they are good at what they are doing. There are some medicine companies that have spread too much and have had to give up some of what they have been doing. This link provides a very good insight into the issue around Q2. It's in Danish. app.marketingplatform.com Price target: Trading View a year 860. Handelsbanken SE 3 years 925. Danske Bank 900. This chart is YTD, but the trend lines are drawn after a longer chart 1Y. Novo Nordisk is on a rising trend as evidenced by MA. Volume supports the trend as price top respond to volume top and price bottom respond to volume bottom. On volume balance OVB rising 22 days back. There was a dive after Q2 on August 4th, but the next day there are more people buying in than selling out on the first day. RSI 21 slightly below 50. Oscillators and MA stand on sell one day, neutral a week and buy a month. Considers the stock technically positive for medium long time. Disclaimer: I have a position in the stock. Remember you need do your own research and assessment before buying and selling. Sources: Trading View.
OMXCOP:NOVO_B
by scorpiris
BAVA MonkeyPox VaccineHere we go again...? "The spread of monkeypox boosted the shares of Bavarian Nordic A/S, which says it’s the only company to make a vaccine approved for the viral infection. The Danish company gained as much as 26% in Copenhagen trading on Thursday after saying it had secured a contract to supply its smallpox shot -- which is also cleared against monkeypox -- to an undisclosed European country. Monkeypox, a virus that is endemic in some forested parts of central and west Africa, has been found in a handful of cases in the UK, Spain and Portugal in recent days and in one person in the US. The World Health Organization said Wednesday it was monitoring a situation that 'is evolving rapidly.' " www.bloomberg.com
OMXCOP:BAVALong
by reiiss7
Carlsberg Hangover Incoming? Carlsberg Short Term - We look to Sell at 972 (stop at 1037) Preferred trade is to sell into rallies. We have a 61.8% Fibonacci pullback level of 984 from 1131 to 747. 200 1day MA is at 1012. Previous resistance located at 980. Our profit targets will be 747 and 712 Resistance: 900 / 980 / 1100 Support: 800 / 750 / 700 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
OMXCOP:CARL_BShort
by Saxo